HQL
Tekla Life Sciences Investors
17.70$
+0.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q1 25 | Q3 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.5% | +0.0% | +4.3% | +0.0% | -7.0% | +9.8% | +0.0% | +4.2% | -10.7% | +25.3% | +9.3% | |
| – | +246.2% | -94.7% | +331.6% | -99.5% | +36,887.6% | -96.6% | +0.0% | +63.8% | -84.9% | +2,844.2% | +70.0% | |
| – | -99.8% | +0.0% | +84.7% | +0.0% | -42.0% | – | – | – | +0.0% | +7,553,700.0% | – | |
| – | -99.8% | +0.0% | +84.7% | +0.0% | +1,854,215.9% | -9.2% | +0.0% | -100.0% | +1,216,121,500.0% | -99.4% | +1,027.4% | |
| – | -79.9% | 0.0% | -97.9% | -1.5% | +39,255.9% | -97.8% | +0.0% | +104.6% | +2,664.0% | -82.2% | +11.4% | |
| – | -100.0% | – | -100.0% | – | +69.2% | – | – | – | – | – | – | |
| – | +30.0% | +0.0% | -40.3% | +0.0% | -93.4% | +31.9% | +0.0% | +1.0% | +1,633.0% | -88.8% | +39.0% | |
| – | +375.0% | -69.7% | +96.9% | +0.0% | – | – | +0.0% | +1.0% | +1,596.5% | -95.2% | +14.4% | |
| – | – | -99.9% | +84,043.4% | -99.9% | – | – | – | – | – | – | – | |
| – | +44.0% | +0.0% | – | – | – | – | +0.0% | -99.2% | +365,075.4% | -89.0% | -97.5% | |
| – | -8.6% | +0.0% | +6.2% | +0.0% | -4.9% | +9.7% | +0.0% | +4.2% | -13.9% | +29.7% | +9.2% | |
| – | -82.4% | +0.0% | +181.0% | +0.0% | -105.5% | – | +0.0% | +46.2% | -169.2% | – | +43.5% | |
| – | -99.9% | +99,902.5% | -99.9% | +99,900.2% | +2.2% | +2.1% | +0.0% | +5.2% | +0.3% | +0.0% | +5.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.